Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy

References

• Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the royal college of general practitioners’ oral contraception study. Am J Obstet Gynecol 2017;216:580.e1–9
   PubMed Web of Science ®Google Scholar
• Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2017 Oct 16. [Epub ahead of print]
   PubMedGoogle Scholar
• Whitehead MI, Townsend PT, Pryse-Davies J, et al. Actions of progestins on the morphology and biochemistry of the endometrium of postmenopausal women receiving low-dose estrogen therapy. Am J Obstet Gynecol 1982;142:791–5
   PubMed Web of Science ®Google Scholar
• Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:1599–605
   PubMed Web of Science ®Google Scholar
• King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986;46:1062–6
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370–5
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234–40
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–7
   PubMed Web of Science ®Google Scholar
• Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197:139.e1–7
   PubMed Web of Science ®Google Scholar
• Reed SD, Voigt LF, Beresford SAA, Hill DA, Doherty JA, Weiss NS. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004;191:1146–51
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015;213:469–78
   PubMed Web of Science ®Google Scholar
• Pal N, Broaddus RR, Urbauer DL, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol 2018;131:109–16
   PubMed Web of Science ®Google Scholar
• Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms–a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 2012;19:886–93
   PubMed Web of Science ®Google Scholar
• Depypere HT, Hillard T, Erkkola R, et al. A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause. Eur J Obstet Gynecol Reprod Biol 2010;153:176–80
   PubMed Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211–17
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014;124:292–9
   PubMed Web of Science ®Google Scholar
• Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813–17
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grénman S, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol Stockh Swed 2016;55:188–92
   PubMed Web of Science ®Google Scholar
• Siegelmann-Danieli N, Katzir I, Landes JV, et al. Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast Cancer Res Treat 2018;167:257–62
   PubMed Web of Science ®Google Scholar
• Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J (Clin Res Ed) 1983;287:1241–5
   PubMed Web of Science ®Google Scholar
• Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016;19:316–28
   PubMed Web of Science ®Google Scholar
• Gillet JY, Andre G, Faguer B, Erny R, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 1994;19:103–15
   PubMed Web of Science ®Google Scholar
• Moyer DL, de Lignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993;59:992–7
   PubMed Web of Science ®Google Scholar
• Lorrain J, Lalumiere G, Caron P. The effects of oral micronized progesterone on bleeding patterns, endometrial histology and bone density in postmenopausal women on hormone replacement therapy. Int J Gynaecol Obstet 1994;46(Suppl 1):77
   Google Scholar
• Jondet M, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Pélissier C. Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. Maturitas 2002;41:115–21
   PubMed Web of Science ®Google Scholar
• Di Carlo C, Tommaselli GA, Gargano V, Savoia F, Bifulco G, Nappi C. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 2010;13:442–6
   PubMed Web of Science ®Google Scholar
• Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2010;172:1394–403
   PubMed Web of Science ®Google Scholar
• Fournier A, Dossus L, Mesrine S, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008. Am J Epidemiol 2014;180:508–17
   PubMed Web of Science ®Google Scholar
• Serfaty D, Bruhat MA, Colau JC, et al. [Compliance with hormone replacement therapy in menopause: effect of an original education program. The COMET study]. Gynecol Obstet Fertil 2002;30:374–82
   PubMedGoogle Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG 2000;107:1392–400
   PubMed Web of Science ®Google Scholar